GEP20227344B - Pyrimidine compound as jak kinase inhibitor - Google Patents

Pyrimidine compound as jak kinase inhibitor

Info

Publication number
GEP20227344B
GEP20227344B GEAP201815340A GEAP2018015340A GEP20227344B GE P20227344 B GEP20227344 B GE P20227344B GE AP201815340 A GEAP201815340 A GE AP201815340A GE AP2018015340 A GEAP2018015340 A GE AP2018015340A GE P20227344 B GEP20227344 B GE P20227344B
Authority
GE
Georgia
Prior art keywords
kinase inhibitor
pyrimidine compound
jak kinase
vitiligo
basis
Prior art date
Application number
GEAP201815340A
Other languages
English (en)
Inventor
Ryan Hudson
Gary E L Brandt
Marta Dabros
Jennifer Kozak
Jerry Nzerem
Robert Murray Mckinnell
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of GEP20227344B publication Critical patent/GEP20227344B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)
GEAP201815340A 2017-10-27 2018-10-26 Pyrimidine compound as jak kinase inhibitor GEP20227344B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27

Publications (1)

Publication Number Publication Date
GEP20227344B true GEP20227344B (en) 2022-01-25

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201815340A GEP20227344B (en) 2017-10-27 2018-10-26 Pyrimidine compound as jak kinase inhibitor

Country Status (38)

Country Link
US (7) US10308646B2 (enExample)
EP (1) EP3672965B1 (enExample)
JP (1) JP7218364B2 (enExample)
KR (1) KR102613503B1 (enExample)
CN (1) CN111247142B (enExample)
AR (1) AR113803A1 (enExample)
AU (1) AU2018354370B2 (enExample)
BR (1) BR112020008015A2 (enExample)
CA (1) CA3074034A1 (enExample)
CL (1) CL2020001090A1 (enExample)
CR (1) CR20200180A (enExample)
CU (1) CU24671B1 (enExample)
DK (1) DK3672965T3 (enExample)
DO (1) DOP2020000083A (enExample)
EA (1) EA202091016A1 (enExample)
EC (1) ECSP20023795A (enExample)
ES (1) ES2932526T3 (enExample)
GE (1) GEP20227344B (enExample)
HR (1) HRP20221221T1 (enExample)
HU (1) HUE060401T2 (enExample)
IL (1) IL274037B2 (enExample)
LT (1) LT3672965T (enExample)
MA (1) MA49956B1 (enExample)
MD (1) MD3672965T2 (enExample)
MX (1) MX2020004255A (enExample)
NI (1) NI202000032A (enExample)
PE (1) PE20201495A1 (enExample)
PH (1) PH12020500528A1 (enExample)
PL (1) PL3672965T3 (enExample)
PT (1) PT3672965T (enExample)
RS (1) RS63608B1 (enExample)
SG (1) SG11202001706RA (enExample)
SI (1) SI3672965T1 (enExample)
SM (1) SMT202200409T1 (enExample)
TW (1) TWI789446B (enExample)
UA (1) UA125130C2 (enExample)
WO (1) WO2019084383A1 (enExample)
ZA (1) ZA202001641B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20227344B (en) 2017-10-27 2022-01-25 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor
CN115925705B (zh) * 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
TW202106682A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 作為jak激酶抑制劑之酯類及碳酸酯類嘧啶化合物
TW202106681A (zh) * 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
MX2023001259A (es) * 2020-07-28 2023-05-15 Arcutis Biotherapeutics Inc Formulaciones tópicas que contienen inhibidor de jak y laureth-4.
CA3190539A1 (en) * 2020-08-26 2022-03-03 William Greenlee Modulators of myc family proto-oncogene protein
US20230374124A1 (en) * 2020-10-08 2023-11-23 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療fxr誘發之搔癢之il-31調節劑
CN119013277A (zh) 2021-10-25 2024-11-22 凯麦拉医疗公司 Tyk2降解剂和其用途
EP4447930A1 (en) 2021-12-15 2024-10-23 Arcutis Biotherapeutics, Inc. Stable formulations of shr0302
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432799C (en) 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2008525422A (ja) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
CN101360740A (zh) 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
UY30444A1 (es) 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (enExample) * 2014-08-21 2018-03-31
WO2016052930A1 (ko) * 2014-09-30 2016-04-07 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
KR20180011272A (ko) * 2015-05-28 2018-01-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 나프티리딘 화합물
WO2017044434A1 (en) * 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
GEP20227344B (en) * 2017-10-27 2022-01-25 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
TW202106682A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 作為jak激酶抑制劑之酯類及碳酸酯類嘧啶化合物

Also Published As

Publication number Publication date
ZA202001641B (en) 2021-04-28
CN111247142B (zh) 2022-12-02
EP3672965A1 (en) 2020-07-01
SMT202200409T1 (it) 2022-11-18
US10308646B2 (en) 2019-06-04
US20210214349A1 (en) 2021-07-15
BR112020008015A2 (pt) 2020-10-27
LT3672965T (lt) 2022-10-10
JP7218364B2 (ja) 2023-02-06
TW201930304A (zh) 2019-08-01
SI3672965T1 (sl) 2022-11-30
CA3074034A1 (en) 2019-05-02
US12172994B2 (en) 2024-12-24
CR20200180A (es) 2020-08-12
EP3672965B1 (en) 2022-09-07
RS63608B1 (sr) 2022-10-31
SG11202001706RA (en) 2020-03-30
DOP2020000083A (es) 2020-08-15
IL274037B1 (en) 2023-07-01
US10988470B2 (en) 2021-04-27
US10562894B2 (en) 2020-02-18
TWI789446B (zh) 2023-01-11
CN111247142A (zh) 2020-06-05
US10774080B2 (en) 2020-09-15
UA125130C2 (uk) 2022-01-12
US20240158389A1 (en) 2024-05-16
MD3672965T2 (ro) 2022-12-31
EA202091016A1 (ru) 2020-07-17
PT3672965T (pt) 2022-09-29
US20200140430A1 (en) 2020-05-07
AR113803A1 (es) 2020-06-10
MA49956B1 (fr) 2022-11-30
US11420965B2 (en) 2022-08-23
JP2021501151A (ja) 2021-01-14
ES2932526T3 (es) 2023-01-20
CL2020001090A1 (es) 2020-08-21
NI202000032A (es) 2020-10-09
KR20200078517A (ko) 2020-07-01
IL274037B2 (en) 2023-11-01
MA49956A (fr) 2020-07-01
HUE060401T2 (hu) 2023-02-28
ECSP20023795A (es) 2020-06-30
CU24671B1 (es) 2023-07-12
IL274037A (en) 2020-06-30
PE20201495A1 (es) 2020-12-29
WO2019084383A1 (en) 2019-05-02
DK3672965T3 (da) 2022-10-03
PH12020500528A1 (en) 2021-06-07
AU2018354370B2 (en) 2023-04-27
HRP20221221T1 (hr) 2022-12-09
AU2018354370A1 (en) 2020-04-09
PL3672965T3 (pl) 2023-01-16
US20220396573A1 (en) 2022-12-15
US20190241555A1 (en) 2019-08-08
CU20200053A7 (es) 2021-03-11
US20200369660A1 (en) 2020-11-26
MX2020004255A (es) 2020-07-29
KR102613503B1 (ko) 2023-12-13
US11814377B2 (en) 2023-11-14
US20190127364A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
ZA202405294B (en) Heterocyclic compounds as immunomodulators
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
MY210070A (en) Heterocyclic compounds as immunomodulators
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MY199220A (en) Heterocyclic compounds as immunomodulators
MX387984B (es) Inhibidor del egfr y preparación y aplicación del mismo.
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
JOP20190076A1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
PH12020550499A1 (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
MX2016012480A (es) Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2015014944A (es) Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer.
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MY196497A (en) Pyrido[3, 4-D]Pyrimidine Derivative And Pharmaceutically Acceptable Salt Thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones